Ionis Pharmaceuticals — Jul 29, 2026 release

net product sales of $5 million and $32 million in the second quarter and first half of 2026, respectively   ■ Demonstrated continued strong demand in FCS, offset by the reduced net price effective April 1, 2026   ■ On track to achieve full year 2026 product sales of $100-110 million, in line with revenues generated in 2025   o sHTG U.S. launch demonstrating early momentum following June 2026 approval   o FCS launch outside the U.S. underway; sHTG marketing application under review in the European Union (EU) with potential launch in 2027   o Results from the CORE and CORE2 open-label extension study (CORE-OLE) will be presented at the European Society of Cardiology (ESC) Congress in August 2026   • DAWNZERA ® (donidalorsen), the first and only RNA-targeted prophylactic therapy for hereditary angioedema (HAE) in patients 12 years of age and older   o Generated U.S. net product sales of $26 million and $42 million in the second quarter and first half of 2026, respectively; second quarter net product sales increased 63% compared to the first quarter of 2026   o On track to achieve full year 2026 product sales of $110-120 million, representing a continuing driver of year-over-year revenue growth   o Launch outside the U.S. underway, with new market approvals in the EU   2 •